Zacks Investment Research · Jan 13, 2022
IMV Doses First Patient in the Mid-Stage Study With Keytruda
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
IM
NASDAQ · IMV
IMV Inc.
Healthcare · Biotechnology
$0.82
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 6:44 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.63M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 44.89K
- Avg. volume
- 163.85K
Price performance
IMV price history
1M range · 0 trading sessions · Daily adjusted prices
IMV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest IMV news
The latest Smart Investors Daily articles mentioning IMV.
Stock researchCompany · Overview
IMV research
Overview
Company profile and research snapshot.
Company profile
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 2, 2023 | HC Wainwright & Co. | Neutral | — |
| Mar 16, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 13, 2023 | HC Wainwright & Co. | Buy | — |
| Dec 21, 2022 | HC Wainwright & Co. | Buy | — |
| Sep 22, 2021 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jan 12, 2022
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen, Inc. (NASDAQ: BIIB) shares were reacting to a verdict from the Centers for Medicare and Medicaid Services regarding limited coverage for its Alzheimer's disease drug Aduhelm. The CMS statement suggested that it would cover the cost of treatment only if patients are enrolled in clinical studies. "Biogen believes that the proposed coverage with evidence development (CED) decision for anti-amyloid therapies denies nearly all Medicare beneficiaries from accessing ADUHELM," the company said in a statement. It is imperative to change this draft decision to be aligned with reimbursement for other therapies for progressive diseases, where patients have immediate and equal access to medicines approved by the FDA, it added. The stock was slipping 9.22% to $219.25 in premarket trading. Aclaris Announces Departure Of Chief Medical Officer Providing a R&D update, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said David Gordon, its chief medical officer left the company, effective Jan. 7. The company also announced update on its two Phase 2 programs that evaluate zunsemetinib in subjects with moderate to severe rheumatoid arthritis and in subjects with moderate to severe hidradenitis suppurative. The stock was slipping 2.80% at $12.50 in premarket trading. Click here to access Benzinga's FDA Calendar Pfizer Announces Positive Phase 3 Data For Prevnar 20 Co-Administered With COVID-19 Vaccine Pfizer Inc. (NYSE: PFE) announced positive top-line results from a Phase 3 study describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the U.S., 65 years of age or older when administered at the same time as the ...
The Motley Fool · Aug 12, 2021
IMV Inc. (IMV) Q2 2021 Earnings Call Transcript
IMV earnings call for the period ending June 30, 2021.
Benzinga · Jun 30, 2021
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ: TXG) Ambrx Biopharma Inc. (NYSE: AMAM) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ( announced positive Phase 1b data for Schizophrenia treatment) Graphite Bio, Inc. (NASDAQ: GRPH) (IPOed Friday) Harvard Bioscience, Inc. (NASDAQ: HBIO) Intellia Therapeutics, Inc. (NASDAQ: NTLA) (follow-through buying triggered after the first-ever human trial results for gene-editing therapy) Intuitive Surgical, Inc. (NASDAQ: ISRG) Lantheus Holdings, Inc. (NASDAQ: LNTH) MiMedx Group, Inc. (NASDAQ: MDXG) Moderna, Inc. (NASDAQ: MRNA) ( reacted to positive COVID-19 vaccine data as well as authorization for emergency use of the vaccine in India) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) ResMed Inc. (NYSE: RMD) Sesen Bio, Inc. (NASDAQ: SESN) ShockWave Medical, Inc. (NASDAQ: SWAV) Verve Therapeutics, Inc. (NASDAQ: VERV) Zoetis Inc. (NYSE: ZTS) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 29) Achilles Therapeutics plc (NASDAQ: ACHL) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Elevation Oncology, Inc. (NASDAQ: ELEV) (IPOed Friday) Celyad Oncology SA (NASDAQ: CYAD) Exelixis, Inc. (NASDAQ: EXEL) Freeline Therapeutics Holdings plc (NASDAQ: FRLN) Gemini Therapeutics, Inc. (NASDAQ: GMTX) Global Blood Therapeutics, Inc. (NASDAQ: GBT) IMV Inc. (NASDAQ: IMV) Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Medicenna Therapeutics Corp. (NASDAQ: MDNA) Mersana Therapeutics, Inc. (NASDAQ: MRSN) Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) (announced prioritization of its pipeline programs) Tempest Therapeutics, Inc. (NASDAQ: TPST) Terns Pharmaceuticals, Inc. (NASDAQ: TERN) VectivBio Holding AG (NASDAQ: VECT) Vivos Therapeutics, Inc. (NASDAQ: VVOS) Stocks In Focus Altimmune Winds Up COVID-19 Program Altimmune, Inc. (NASDAQ: ALT) provided an update on the Phase 1 AdCOVID clinical trial evaluating the safety and immunogenicity of the intranasally administered vaccine candidate, showing lower than expected immune responses for each of the immune parameters tested. Moving forward, Altimmune will focus its resources on the development of ALT-801 and HepTcell, its novel peptide-based therapeutics for obesity and liver diseases, the company said. Additionally, the company said it's unable to enroll subjects in the final cohort of the Phase 1/2 trial of T-COVID, which is being evaluated for the prevention of clinical worsening in patients with early COVID-19. ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
